EMERYVILLE, Calif.--(BUSINESS WIRE)--Nafsika Georgopapadakou, PhD, Vice President, Research at NovaBay Pharmaceuticals, Inc., (AMEX: NBY), was interviewed by television stations across the country this week to discuss the growing problem of methicillin-resistant Staphylococcus aureus (MRSA), the rise in “super bugs” (multi-drug-resistant pathogens) and steps that can be taken to prevent systemic bacterial infections. The interviews were part of a broad patient education initiative undertaken by NovaBay to create not only awareness of this looming threat, but also to promote new thinking and approaches to treating “superbugs.”
